UCB7362 is an orally active plasmepsin X (PMX) inhibitor currently investigated for the treatment of malaria. Plasmepsins are aspartyl proteases produced by the malaria parasite Plasmodium falciparum, and PMX is... UCB7362 is estimated to achieve a significant reduction in asexual blood-stage parasites.
- Mechanism
- Curator reviewed · 2 references
Plasmepsins are aspartic acid proteases produced by malaria Plasmodium parasites. Several plasmepsins have been identified, and each one of them has a specific function. Plasmepsin X (PMX) controls parasite egress and invasion of erythrocytes and is essential during the red blood cell stages. UCB7362 binds to and inhibits PMX, disrupting the malaria parasite life cycle.
- Formula / weight
- C25H26ClN5O3 · 479.97 g/mol (avg)
- Code names
- UCB7362
Resolves to
AWSRDDSRQUJMAJ-LCAJTWGOSA-NSMILESC[C@H]1C[C@H](CCO1)N1C(=O)C[C@](C)(NC1=N)C1=C(Cl)C(NC(=O)C2=CC=CC(=C2)C#N)=CC=C1What you can answer from here — as of April 02, 2025
Which drugs share a target with UCB7362, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account